scholarly journals A Dose-finding Study of Glycosylated G-CSF (Lenograstim) Combined with CHOP Therapy for Stem Cell Mobilization in Patients with Non-Hodgkin's Lymphoma

2003 ◽  
Vol 33 (2) ◽  
pp. 78-85 ◽  
Author(s):  
K. Takeyama
Keyword(s):  
Stem Cell ◽  
Hodgkin’S Lymphoma ◽  
Stem Cell Mobilization ◽  
Dose Finding ◽  
Hodgkin's Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
Finding Study ◽  
Dose Finding Study ◽  
Cell Mobilization ◽  
Chop Therapy

Intensive Dose Ifosfamide and Etoposide with G-CSF for Stem Cell Mobilization in Patients with Non-Hodgkin's Lymphoma

1999 ◽  
Vol 35 (3-4) ◽  
pp. 317-324 ◽  
Author(s):  
M. L. Donato ◽  
R. E. Champlin ◽  
K. W. van Besien ◽  
M. Korbling ◽  
F. Cabanillas ◽  
...  
Keyword(s):  
Stem Cell ◽  
Hodgkin’S Lymphoma ◽  
Stem Cell Mobilization ◽  
Hodgkin's Lymphoma ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
Cell Mobilization

Effects of Pretransplantation Treatment With Rituximab on Outcomes of Autologous Stem-Cell Transplantation for Non-Hodgkin's Lymphoma

2004 ◽  
Vol 22 (22) ◽  
pp. 4561-4566 ◽  
Author(s):  
Amy L. Hoerr ◽  
Feng Gao ◽  
Josephine Hidalgo ◽  
Divya Tiwari ◽  
Kristie A. Blum ◽  
...  
Keyword(s):  
Overall Survival ◽  
Stem Cell ◽  
Hodgkin’S Lymphoma ◽  
Stem Cell Mobilization ◽  
Hodgkin's Lymphoma ◽  
Post Transplantation ◽  
Intermediate Grade ◽  
Non Hodgkin's Lymphoma ◽  
Cell Mobilization ◽  
Disease Free

Purpose To analyze the effects of preautografting treatment with rituximab (R) on stem-cell mobilization, post-transplantation complications, engraftment, disease-free survival, and overall survival in patients with non-Hodgkin's lymphoma (NHL). Patients and Methods Single-institution retrospective comparative outcome analysis in a cohort of 273 relapsed chemosensitive NHL patients of whom 127 (47%) received R pretransplantation. Results R was administered a median of 3 months before autologous transplantation. When compared to the nonrituximab group, R patients were older (56 v 50 years; P < .001), and had delays in post-transplantation platelets recovery (39 v 27 days; P = .001). Pretransplantation R did not affect stem-cell mobilization, post-transplantation early complications, duration of hospitalization, or mortality rates at days 30 and 100. In contrast to patients with low-grade NHL, both disease-free and overall survival rates were significantly better when R was included in the pretransplantation salvage therapy for patients with intermediate-grade NHL. Conclusion In this large, single-center retrospective analysis, pretransplantation treatment with R was associated with improved survival in patients with intermediate-grade NHL, at the price, however, of a delay in platelet engraftment.

Outcomes of autologous bone marrow transplantation in non-Hodgkin's lymphoma patients who failed peripheral blood stem cell mobilization

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 7040-7040
Author(s):  
C. B. Sola ◽  
L. Silva ◽  
R. Saliba ◽  
M. De Lima ◽  
S. Giralt ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Stem Cell ◽  
Median Time ◽  
Peripheral Blood ◽  
Hodgkin’S Lymphoma ◽  
Stem Cell Mobilization ◽  
Hodgkin's Lymphoma ◽  
Cell Dose ◽  
Non Hodgkin's Lymphoma ◽  
Cell Mobilization

7040 Background: Patients (pts) with relapsed/refractory non-Hodgkin's lymphoma (NHL) who fail to mobilize adequate peripheral blood stem cells (PBSC) often undergo bone marrow (BM) harvest for autologous transplantation. The outcome of these pts is not known. Methods: In this retrospective study (May 1996-September 2006), we identified 36 out of a total of 750 pts with advanced NHL, who failed to collect adequate PBSC and subsequently underwent BM harvest followed by ABMT. Decision to harvest BM was left to the treating clinician. Median age at transplant was 53 years (range 15–73). Twenty of 36 pts (55%) were male. Histology was intermediate grade in 31 (86%) patients and low grade in 5 (14%). Twelve pts (35%) had history of BM involvement with lymphoma. Median number of chemotherapy cycles received prior to mobilization was 3 (range 1–6). At the time of stem cell mobilization 18 (50%) were in complete remission (CR), 13 (37%) were in partial remission (PR) and 5 (13%) had progressive disease (PD). Twenty four (67%) pts underwent chemo-mobilization and 12 (33%) were mobilized with cytokines alone. Results: The median total nucleated cell dose and CD34+ cell dose harvested/kg were 3.72 x 108 (range 0.25–58.0) and 1.6 x 106 (range 0.03–5.8), respectively. After ABMT, 33 of 35 evaluable (94%) pts engrafted neutrophils with median time to ANC 0.5 x 109/L of 23 days (range 8–47). Median time to platelet count 20 x 109/L was 63 days (range 11–375). Two of 35 (6 %) evaluable pts failed to engraft. After ABMT, 25/36 (70%) pts achieved a CR. The incidence of NRM at 100 days was 15%. Sixteen (45%) pts relapsed at a median of 11 months (range 2–59) from ABMT. After a median follow-up of 34 months (range 0.4–100), the 3-year OS and DFS were 47% and 35%, respectively. Causes of death were: disease progression/relapse in 15 (60%), secondary malignancy in 3 (12%), multiorgan failure in 5 (20%), and unknown in 2 (8%). Conclusions: ABMT is feasible in pts who fail to mobilize adequate PBSC, however, these pts have longer time to engraftment. Although the CR rate after transplant is high, the NRM is higher than expected. Non-myeloablative allogeneic transplantation may provide better outcomes with similar toxicity and needs to be further studied. No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document